CompX (CIX) Q4 2025 earnings review
Margins Expand Despite Top-Line Reversal
CompX delivered a mixed Q4 2025: revenue growth suddenly reversed into negative territory (-1.8% YoY), but disciplined cost of sales management drove a robust 14.3% YoY increase in Operating Income. The revenue decline was isolated to the Security Products segment's healthcare market, breaking a strong three-quarter streak of top-line growth. However, significant gross margin expansion across both Security and Marine segments protected the bottom line, pushing full-year EPS to $1.58, a 17% YoY improvement.
🐂 Bull Case
Despite lower Q4 volumes, gross margins expanded by 345 basis points YoY to 32.1%. Management successfully navigated the volume drop through favorable mix and segment-level margin improvements.
The Marine Components segment continues to be a reliable growth engine, driving higher sales into industrial, government, and towboat markets, offsetting weaknesses in other areas.
🐻 Bear Case
The sudden drop in Security Products sales to the healthcare market dragged total Q4 revenue into a contraction, raising questions about end-market demand durability.
While gross margins improved, SG&A expenses continued to climb ($6.5M vs $6.1M YoY) even as revenue shrank, highlighting cost stickiness if volume declines persist.
⚖️ Verdict: ⚪
Neutral. The ability to expand operating margins on lower revenue is a testament to strong operational execution. However, the abrupt reversal in top-line growth from +19% in Q3 to -1.8% in Q4 warrants caution.
Key Themes
Gross Margin Profile Accelerating
The standout metric of Q4 was the gross margin improvement. Cost of sales dropped by 6.5% YoY ($25.6M vs $27.4M), outpacing the 1.8% revenue decline. This resulted in a gross margin of 32.1% (up from 28.6% in 24Q4). Management attributed this directly to improved gross margins at both the Security Products and Marine Components segments.
Marine Components Serving as the Growth Anchor
Marine Components demonstrated stable, robust demand, growing sales into the industrial, towboat, and government markets. This segment successfully counterbalanced the specific shortfalls experienced in Security Products during Q4.
Government Security Market Carries the Year
While healthcare stumbled in Q4, the full-year narrative was heavily supported by the government security market. Increased full-year Security Products sales to government entities show that when federal/state projects are active, they drive significant volume.
Healthcare Market Reversing
Management explicitly cited 'lower Security Products sales to the healthcare market' as the primary reason for the Q4 top-line contraction. This contradicts the positive momentum seen in Q1-Q3 and introduces a new vector of demand weakness.
Sequential Demand Decelerating
After posting three consecutive quarters of revenue at or above $40.0M, Q4 sales dipped to $37.7M. This sequential deceleration suggests that the inventory restocking or project-based tailwinds experienced earlier in 2025 may be exhausting.
SG&A Expense Creep Contradicts Volume Decline
Despite revenue falling by $0.7M YoY in Q4, Selling, General and Administrative expenses actually increased from $6.1M to $6.5M. This 6.5% YoY increase in SG&A amidst a top-line contraction indicates negative operating leverage below the gross profit line.
Macro Exposure to Raw Material Volatility
As noted in the risk factors, the company remains highly sensitive to fluctuations in the prices of zinc, brass, aluminum, and steel. While they managed costs effectively in Q4, any newly introduced tariffs on imported raw materials (a specific cited risk) could quickly erode the impressive 32.1% gross margin.
Other KPIs
Accelerating significantly from $17.0M in 2024 (+32.9% YoY). This underscores a highly successful year of margin recovery and volume execution, even with the Q4 top-line stumble.
Up 8.5% YoY from $145.9M in 2024. The full-year picture remains strong, driven heavily by Q2 and Q3 outperformance before the Q4 normalization.
Decelerating from $4.7M in 2024. Q4 interest income also fell to $0.7M from $0.9M YoY, reflecting changes in cash balances and prevailing yield environments.
Key Questions
Healthcare Security Contraction
What drove the sudden decline in Security Products sales to the healthcare market in Q4? Is this a timing issue with specific customer orders, or a broader structural slowdown in hospital/clinic capital expenditures?
Gross Margin Sustainability
You achieved a 32.1% gross margin this quarter despite lower volumes. How much of this was driven by favorable product mix versus structural manufacturing efficiencies or lower raw material costs?
SG&A Leverage
SG&A expenses grew 6.5% YoY in Q4 despite the decline in revenue. What specific investments or inflationary pressures are driving these costs, and how should we model SG&A run-rates for 2026?